http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-134994-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afc5d8c9ee6673323cee3e2d19bc5146
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q5-006
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H04R29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H04R27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
filingDate 2002-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15d2124d59adf289db00476fbb4493f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67a806c82e8d1647253a4b5f5ad84b67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e610140ec1d63d710123a1bc0fd699e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e523e7eab1d1371cd953782cfbc25eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c84ef529566044413914aff6f23ae394
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b875f4242cf12302c49a1d6b31c60d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58e0e7ceebda964a69e992cb80e013da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6663f5f3ae81d5dba18a09c8b196daa
publicationDate 2008-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MY-134994-A
titleOfInvention Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
abstract THE PRESENT INVENTION IS DIRECTED TO NOVEL 1,2,4-THIADIAZOL-2-IUM DERIVATIVES USEFUL AS AGONISTS OR ANTAGONISTS OF THE MELANOCORTIN RECEPTOR. MORE PARTICULARLY, THE COMPOUNDS OF THE PRESENT INVENTION ARE USEFUL FOR THE TREATMENT OF METABOLIC, CNS AND DERMATOLOGICAL DISORDERS SUCH AS OBESITY, IMPAIRED ORAL GLUCOSE TOLERANCE, ELEVATED BLOOD GLUCOSE LEVELS, TYPE II DIABETES, SYNDROME X, DIABETIC RETINOPATHY, SPINAL CORD INJURY, NERVE INJURY, ACUTE NEURODEGENERATIVE DISORDERS, CHRONIC NEURODEGENERATIVE DISORDERS, PLEXOPATHIES, MALE ERECTILE DYSFUNCTION, DRY EYES, ACNE, DRY SKIN, AGED SKIN, SEBORRHEIC DERMATITIS, ROSACEA, EXCESSIVE EAR WAX, MEIBOMIAN GLAND DISORDER, PSEUDOFOLLICULITIS, YEAST INFECTIONS, DANDRUFF, HIDRADENITIS SUPPURATIVA, OCULAR ROSACEA AND ECCRINE GLAND DISORDER.
priorityDate 2001-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419724048
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID4932
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22736960
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID4932
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419508054
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5793

Total number of triples: 69.